
Investigative Agent Elicits Responses in Phase 3 Breast Cancer Trial
Treatment with the investigative agent GLSI-100 (GP2 plus GM-CSF) demonstrated an increased immune response over time in patients with HER2-positive breast cancer following surgery, according to preliminary immune response data from the phase 3 FLAMINGO-01 …